BACKGROUND/AIMS: Treatments of diabetic nephropathy (DN) delay the onset of end-stage renal disease. We report the results of safety/tolerability studies in patients with overt nephropathy and type 1/type 2 diabetes treated with pyridoxamine, a broad inhibitor of advanced glycation. METHODS: The two 24-week studies were multicenter Phase 2 trials in patients under standard-of-care. In PYR-206, patients were randomized 1:1 and had baseline serum creatinine (bSCr) or=2.0 but or=1.3 mg/dl, type 2 diabetes), a treatment effect was observed on the rise in serum creatinine (p = 0.007). No differences in urinary albumin excretion were seen. Urinary TGF-beta1 also tended to decrease with pyridoxamine (p = 0.049) as did the CML and CEL AGEs. CONCLUSION: These data provide a foundation for further evaluation of this AGE inhibitor in DN.
Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. Publishing Authors By Initials
Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. Journal Published:
PUBLICATION TYPE: Research Support, Non-U.S. Gov
Journal: American journal of nephrology
VOLUME: 27
Page Numbers: 605-14
Journal Abbreviation: Am. J. Nephrol.
ISSN: 1421-9670
DAY: 6
MONTH: 09
YEAR: 2007
Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. Information
Number of References:
LANGUAGE: eng
NlmUniqueID: 8109361
Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. Keywords Mesh Terms:
KEYWORDS:
MESH TERMS:
Chemical & Substance for Abstract: Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. Information
Substance Name:
Registry Number:
Grant and Affiliation Information for Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy.
AFFILIATION: Harvard Medical School, Joslin Diabetes Center, Boston, MA 02215, USA. mark.williams@joslin.harvard.edu
Country: Switzerland
AGENCY:
GRANT:
ACRONYM:
MEDLINETA: Am J Nephrol
REFSOURCE:
DATABASENAME:
ACCESSION NUMBER:
Number Hits: 0
Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy Related Publications